These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 20693595)

  • 1. Evaluation of risk factors for antituberculosis treatment induced hepatotoxicity.
    Singla R; Sharma SK; Mohan A; Makharia G; Sreenivas V; Jha B; Kumar S; Sarda P; Singh S
    Indian J Med Res; 2010 Jul; 132():81-6. PubMed ID: 20693595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of antituberculosis-drug-induced hepatotoxicity and associated risk factors among tuberculosis patients in Dawro Zone, South Ethiopia: A cohort study.
    Wondwossen Abera ; Waqtola Cheneke ; Gemeda Abebe
    Int J Mycobacteriol; 2016 Mar; 5(1):14-20. PubMed ID: 26927985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Drug-induced hepatotoxicity caused by anti-tuberculosis drugs in tuberculosis patients complicated with chronic hepatitis].
    Kaneko Y; Nagayama N; Kawabe Y; Shimada M; Suzuki J; Kunogi M; Matsui Y; Kawashima M; Suzuki J; Ariga H; Oshima N; Masuda K; Matsui H; Nagai H; Tamura A; Akagawa S; Toyoda E; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2008 Jan; 83(1):13-9. PubMed ID: 18283910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity.
    Sarda P; Sharma SK; Mohan A; Makharia G; Jayaswal A; Pandey RM; Singh S
    Indian J Med Res; 2009 Jan; 129(1):64-7. PubMed ID: 19287059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Secular increase in the incidence rate of drug-induced hepatitis due to anti-tuberculosis chemotherapy including isoniazid and rifampicin].
    Nagayama N; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H; Mohri M
    Kekkaku; 2003 Apr; 78(4):339-46. PubMed ID: 12739393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
    Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
    J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antituberculosis drug-induced liver injury in chronic hepatitis and cirrhosis.
    Park WB; Kim W; Lee KL; Yim JJ; Kim M; Jung YJ; Kim NJ; Kim DH; Kim YJ; Yoon JH; Oh MD; Lee HS
    J Infect; 2010 Oct; 61(4):323-9. PubMed ID: 20670648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antituberculosis drugs and hepatotoxicity among hospitalized patients in Jos, Nigeria.
    Isa SE; Ebonyi AO; Shehu NY; Idoko P; Anejo-Okopi JA; Simji G; Odesanya RU; Abah IO; Jimoh HO
    Int J Mycobacteriol; 2016 Mar; 5(1):21-6. PubMed ID: 26927986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antituberculosis drug-induced hepatotoxicity. The role of hepatitis C virus and the human immunodeficiency virus.
    Ungo JR; Jones D; Ashkin D; Hollender ES; Bernstein D; Albanese AP; Pitchenik AE
    Am J Respir Crit Care Med; 1998 Jun; 157(6 Pt 1):1871-6. PubMed ID: 9620920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and risk factors of anti-tuberculosis drug-induced hepatitis in Malaysia.
    Marzuki OA; Fauzi AR; Ayoub S; Kamarul Imran M
    Singapore Med J; 2008 Sep; 49(9):688-93. PubMed ID: 18830542
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
    Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
    J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment.
    Sharma SK; Balamurugan A; Saha PK; Pandey RM; Mehra NK
    Am J Respir Crit Care Med; 2002 Oct; 166(7):916-9. PubMed ID: 12359646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study.
    Pande JN; Singh SP; Khilnani GC; Khilnani S; Tandon RK
    Thorax; 1996 Feb; 51(2):132-6. PubMed ID: 8711642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis.
    Shin HJ; Lee HS; Kim YI; Lim SC; Jung JP; Ko YC; Kwon YS
    Int J Tuberc Lung Dis; 2014 Mar; 18(3):347-51. PubMed ID: 24670574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight loss during tuberculosis treatment is an important risk factor for drug-induced hepatotoxicity.
    Warmelink I; ten Hacken NH; van der Werf TS; van Altena R
    Br J Nutr; 2011 Feb; 105(3):400-8. PubMed ID: 20875187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, clinical and epidemiological risk factors, and outcome of drug-induced hepatitis due to antituberculous agents in new tuberculosis cases.
    Baghaei P; Tabarsi P; Chitsaz E; Saleh M; Marjani M; Shemirani S; Pooramiri MV; Kazempour M; Farnia P; Fahimi F; Mansouri D; Masjedi M
    Am J Ther; 2010; 17(1):17-22. PubMed ID: 19535968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of plasma anti-tuberculosis drug levels with subsequent development of hepatotoxicity.
    Satyaraddi A; Velpandian T; Sharma SK; Vishnubhatla S; Sharma A; Sirohiwal A; Makharia GK; Sinha S; Biswas A; Singh S
    Int J Tuberc Lung Dis; 2014 Feb; 18(2):188-95, i-iii. PubMed ID: 24429311
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphisms of CYP2E1 and GSTM1 loci and susceptibility to anti-tuberculosis drug-induced hepatotoxicity.
    Sharma SK; Jha BK; Sharma A; Sreenivas V; Upadhyay V; Jaisinghani C; Singla R; Mishra HK; Soneja M
    Int J Tuberc Lung Dis; 2014 May; 18(5):588-93. PubMed ID: 24903797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
    Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
    Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens.
    Ho CC; Chen YC; Hu FC; Yu CJ; Yang PC; Luh KT
    Clin Infect Dis; 2009 Jun; 48(11):1526-33. PubMed ID: 19400686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.